Abstract
Cervical cancer remains one of the most common malignancies diagnosed in women in the lesser privileged parts of the world. Unfortunately, most of these cancer cases are diagnosed at a late stage, with subsequent poor prognosis for long-term survival. The associated morbidity and mortality are particularly poignant in an era where advances in medical science have made cervical cancer a mostly preventable disease. In many high-income countries, cervical cancer has become a rare occurrence due to intensive screening and primary preventive strategies.
The world is entering an exciting era in the fight against cervical cancer with new HPV vaccine technology becoming more widely available. Vaccines against oncogenic (cancer causing) strains of human papillomavirus (HPV) will hopefully reduce cervical cancer rates globally. New ways of cost-effective screening with HPV testing may make screening in low resource settings possible and feasible.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferlay J et al (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer 2013. http://globocan.iarc.fr
Franco EL, Schlecht NF, Saslow D (2003) The epidemiology of cervical cancer. Cancer J 9(5):348–359
Stanley M (2007) Prevention strategies against the human papillomavirus: the effectiveness of vaccination. Gynecol Oncol 107(2 Suppl 1):S19–S23
CDC (2015) What women with a positive HPV test result should know. http://www.cdc.gov/std/hpv/common-clinicians/InsertPos.pdf. cited Jan 2015
Stanley M (2008) Immunobiology of HPV and HPV vaccines. Gynecol Oncol 109(2 Suppl):S15–S21
Paavonen J et al (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686):301–314
Joura EA et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574):1693–1702
World Health Organization. Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. WHO guidelines. from: http://www.who.int/reproductivehealth/publications/cancers/screening_and_treatment_of_precancerous_lesions/en/
Benedet JL, Ngan HYS, Hacker NF (2000) Staging classifications and clinical practice guidelines of gynaecologic cancer. http://www.igcs.org/files/TreatmentResources/FIGO_IGCS_staging.pdf
Abdel-Wahab M et al (2013) Status of radiotherapy resources in Africa: an International Atomic Energy Agency analysis. Lancet Oncol 14(4):e168–e175
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Botha, M.H. (2015). Cervical Cancer. In: Droz, JP., Carme, B., Couppié, P., Nacher, M., Thiéblemont, C. (eds) Tropical Hemato-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18257-5_30
Download citation
DOI: https://doi.org/10.1007/978-3-319-18257-5_30
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18256-8
Online ISBN: 978-3-319-18257-5
eBook Packages: MedicineMedicine (R0)